the ideal patient population for the use of nivolumab in treatment of nsclc
Published 8 years ago • 204 plays • Length 1:54Download video MP4
Download video MP3
Similar videos
-
1:19
five-year follow-up results for nivolumab in nsclc
-
1:14
nivolumab compared to docetaxel in patients with nsclc
-
3:17
nivolumab with ipilimumab for small cell lung cancer
-
3:14
comment: nivolumab plus ipilimumab combination for advanced nsclc
-
44:56
advanced nsclc: refining clinical pathways in the rapidly evolving therapeutic landscape
-
4:22
nivolumab in non-small cell lung cancer
-
1:16
nivolumab in the adjuvant setting for melanoma
-
2:08
why checkmate-026 failed to show pfs improvement with nivolumab in lung cancer
-
59:19
precision oncology in early-stage lung cancer, with adjuvant egfr-targeted therapy leading the way
-
3:30
immunotherapy treatments for non-small cell lung cancer (nsclc)
-
17:30
immunotherapy in lung cancer: panacea vs. reality?
-
8:55
options for mrcc after nivolumab
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
5:49
nivolumab extends survival for patients with the most common lung cancer
-
1:33
dr. borghaei on the fda approval of nivolumab in small cell lung cancer
-
1:20
the crossroads of targeted therapy and immunotherapy in lung cancer
-
2:43
clinical factors in the selection of patients for first-line immunotherapy of lung cancer
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc